Alto Neuroscience Reports $319.8M Cash and $25.1M Q3 Net Loss
Alto had approximately $319.8 million in cash, cash equivalents and restricted cash at September 30, 2026, compared with approximately $177.0 million at December 31, 2025. It expects cash to fund planned operations through 2030. Q3 net loss was $25.1 million, versus $14.2 million in Q3 2025.
Alto reported approximately $319.8M in cash, cash equivalents and restricted cash at September 30, 2026, versus approximately $177.0M at December 31, 2025; it expects cash to fund planned operations through 2030. Q3 net loss was $25.1M versus $14.2M in Q3 2025.Material DetailsContext by AI AnalystA…